Saudi Arabia
Tuberculosis profile
Population  2012 28 million
Estimates of TB burden * 2012 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 1.1 (0.11–3.2) 3.9 (0.39–11)
Mortality (HIV+TB only)        
Prevalence  (includes HIV+TB) 4.9 (1.6–10) 17 (5.5–36)
Incidence  (includes HIV+TB) 4.2 (3.7–4.8) 15 (13–17)
Incidence (HIV+TB only)        
Case detection, all forms (%) 87 (77–99)    
TB case notifications 2012        
New cases   (%) Retreatment cases (%)
Smear-positive 2 028 (56) Relapse 91 (39)
Smear-negative 492 (14) Treatment after failure 15 (6)
Smear-unknown / not done 57 (2) Treatment after default 40 (17)
Extrapulmonary 1 022 (28) Other 88 (38)
Other          
Total new 3 599   Total retreatment 234  
           
Other (history unknown)          
Total new and relapse 3 690   Total cases notified 3 833  
New cases Smear-positive Smear-negative/ unknown/
not done
Extrapulmonary
M:F ratio 1.7 1.5 1.5
Age < 15 41 30 57
Laboratories 2012
Smear (per 100 000 population) 0.3
Culture (per 5 million population) 2.1
Drug susceptibility testing (per 5 million population) 2.1
Is second-line drug susceptibility testing available? No
Treatment success rate 2011 (%)        
New smear-positive and/or culture-positive 61   Is rifampicin used
throughout treatment for
new patients?
Yes
New smear-negative/extrapulmonary 61  
Retreatment 63  
TB/HIV 2012 Number (%)
TB patients with known HIV status 3 420 (89)
HIV-positive TB patients 79 (2)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)    
HIV-positive TB patients on antiretroviral therapy (ART)    
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Estimates of MDR-TB burden 2012*   New   Retreatment
% of TB cases with MDR-TB 1.8 (1.4–2.4) 16 (12–21)
MDR-TB cases among notified pulmonary
TB cases
46 (36–62) 37 (28–48)
Reported cases of MDR-TB 2012 New Retreatment Total
Cases tested for MDR-TB      
Laboratory-confirmed MDR-TB cases     20
Patients started on MDR-TB treatment     20
Financing TB control 2013
National TB programme budget (US$ millions)  
% Funded domestically  
% Funded internationally  
% Unfunded  
***
(Rate per 100 000 population per year)
Mortality graph
___ Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
___ Prevalence

(Rate per 100 000 population per year)
Incidence graph
__ Notifications Incidence
___
___ Incidence (HIV+TB only)

Treatment success rate (%)
tx success graph
__ New smear-positive and/or culture-positive
__ New smear-negative/extrapulmonary __
Retreatment

(Number of patients)
CPT ART graph
__ HIV-positive TB patients
__ on CPT __ on ART

Total budget (US$ millions)
Budget funding Graph
__ Funded domestically __ Funded internationally
__ Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 * Ranges represent uncertainty intervals Generated: 2014-04-25 Data: www.who.int/tb/data